Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes (Q42660412)

4 November 2017

Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes (English)

1 reference

4 November 2017

1 reference

1 reference

Thomas Blevins

1

1 reference

4 November 2017

Jenny Han

2

1 reference

4 November 2017

Dawn Nicewarner

3

1 reference

4 November 2017

Steve Chen

4

1 reference

4 November 2017

Juliana H A Oliveira

5

1 reference

4 November 2017

Stephen Aronoff

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

4 November 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

Postgraduate Medicine

1 reference

4 November 2017

122

1 reference

4 November 2017

118-128

1 reference

4 November 2017

3

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

4 November 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

The prevention and treatment of obesity. Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Diabetes medications and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2149

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2149

1 reference

4 November 2017

1 reference